- Secures Foothold as a Game-Changer in the $10 Billion Global Market
- Demonstrates Proprietary Multi-Organ Regeneration Platform
- Regenerates ‘Hyaline Cartilage’ Beyond Symptom Relief; Verified by Harvard Medical School and Global Trials

ROKIT Healthcare (KOSDAQ 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, has become the first Korean firm to succeed in the commercial export of ‘AI-driven cartilage regeneration,’ following its world-first commercialization of AI-driven diabetic foot ulcer treatment. The company has officially exported and supplied hundreds of its ‘AI-driven hyper-personalized cartilage regeneration platforms’ and regeneration kits to major medical sites in Paraguay, South America, and has commenced full-scale commercial prescriptions.

This signifies a transition into the stage of generating actual revenue, moving beyond simple clinical trials or technology exports. It is evaluated as having completed a sequential success formula for organ regeneration platforms, extending from ‘diabetic foot ulcers’ to ‘cartilage.’

The key reason this commercialization is drawing attention from the investment community lies in the quality of cartilage regeneration that overwhelms competitors. Unlike existing stem cell therapies that are limited to forming weak fibrous cartilage (scar tissue), ROKIT Healthcare's platform has achieved the regeneration of ‘Hyaline-like Cartilage,’ the original property of cartilage, in just a single procedure.

The durability of this technology was proven through preclinical studies at Harvard Medical School (MGH), and hyaline-like cartilage regeneration was finally confirmed in clinical trials in Egypt and South America. This has secured a global standard status by proving durability equivalent to natural cartilage.

Notably, Professor Christian Lattermann (President of the International Cartilage Regeneration & Joint Preservation Society (ICRS) and Director of the Cartilage Repair Center at Harvard University), a world-renowned authority, joined the project and is leading it, making the possibility of entry into the U.S. and advanced markets higher than ever.

Building on the success of the South American commercialization, the company plans to expand its supply chain across South America starting from January 2026 and use its U.S. subsidiary, ROKIT America, as a strategic base to advance the integrated sales and after-sales service (AS) network for North and South America.

An official from ROKIT America shared the local sentiment, stating, “ROKIT Healthcare's AI-driven cartilage regeneration commercialization model is currently being noted in the U.S. IR and investment sectors as a significant success story with both scalability and profitability.”

Currently, the South American cartilage regeneration market is rapidly emerging as a trillion-won market, recording a high growth of over 15% annually from a scale of approximately 600 billion won.

An official from ROKIT Healthcare expressed confidence, saying, “This commercialization is a decisive opportunity to show that our technology can be established as a standard treatment in global medical settings. We will become a definitive game changer in the global osteoarthritis market, which is expected to grow to 13 trillion won by 2027.”